- AbbVie will present 15 abstracts, including three oral presentations, in Crohn s disease and ulcerative colitis reinforcing AbbVie s commitment to advancing.
Data illustrates AbbVie s commitment to providing research and innovative solutions that support patients with high disease burden and unmet needOral presentations address treatment of moderate to severe Crohn s disease, including